Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04471-x, published online 25 June 2026. In the version of this article initially published, there was a typographical error in Table 2, row 1, column 5, where “20 (100)” appeared originally as “19 (95.0)” and errors in Table 3, row 1, column 6, where “12 (63.2) appeared originally as “11 (57.9)” and in row 1, column 8, where “40 (81.6)” appeared originally as “39 (79.6).” The tables are now amended in the HTML and PDF versions of the article. Author information Authors and Affiliations Consortia Corresponding authors Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. About this article Cite this article Raab, M.S., Weinhold, N., Kortüm, K.M. et al. Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04551-y Published: Version of record: DOI: https://doi.org/10.1038/s41591-026-04551-y